Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protogene Laboratories Inc.

This article was originally published in Start Up

Executive Summary

Research Products; DNA Chips. Currently, access to DNA microarrays isn't cheap, and its use is restricted mostly to big drug firms and biotechs. Protogene hopes to build cheaper chips with a "printing" approach. Nucleotide bases that make up DNA are spritzed down one at a time on a glass surface to build oligonucleotides. Printing makes it easy to change the chip design at little added cost.

You may also be interested in...

The People Business: The Renaissance of Population Genetics

New technologies enable the rapid processing of genetic information, but since gene data isn't associated with specific diseases and diseased tissues, in and of itself it isn't clinically useful. A new breed of start-ups aims to provide both the phenotypic and genotypic sides of the equation by creating databases of patients and patient samples. Still unclear is how much drug firms will pay for disease-associated gene data; genetics firms are taking various approaches to monetizing their databases, from focusing initially on high-value diagnostics to creating true target-discovery businesses, to selling their data along with associated software and services. There are also ethical issues to hammer out. The new companies must take care to protect patients' rights. They must consider the need for explicit consent to use the information collected from patients, especially when they are participating in research whose purpose is as yet undefined.

Re-Engineering Drug Development II: Clinical Data Collection & Management

Despite a history of failed products, start-up companies are looking to reinvent how data from clinical trials is collected and managed. Firms are trying to replace the point solutions of the past with broad software offerings that can take clients from "site to submission."

Re-Engineering Drug Development I: Simulating Clinical Trials

As the cost and complexity of clinical drug development increases, start-ups are creating new technologies to speed things along. In Part I of our survey, we look at companies adapting computer simulation techniques from industries like aerospace to develop and design clinical trials. The two top simulation companies are thrashing out strategies as they debate adopting product or service business models.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts